scholarly journals Is there a rationale to supplement hepatotropic factors to dogs with multiple acquired portosystemic shunts secondary to congenital portosystemic shunt attenuation?

2021 ◽  
Vol 90 (4) ◽  
pp. 209-215
Author(s):  
L. Van Acker ◽  
H. De Rooster ◽  
G. Serrano ◽  
D. Paepe ◽  
W. De Spiegelaere ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Branched Chain Amino Acids ◽  
Portosystemic Shunt ◽  
Therapeutic Benefits ◽  
Pathological Conditions ◽  
Portosystemic Shunts ◽  
Congenital Portosystemic Shunt ◽  
Show Evidence ◽  
Branched Chain ◽  
Hepatocyte Growth

Experimental rat models and clinical trials in human patients with liver cirrhosis show evidence that supplementation with hepatotropic factors provides therapeutic benefits. This form of support has not yet been described in dogs with multiple acquired portosystemic shunts (MAPSS) despite similarities between both pathological conditions. Especially hepatocyte growth factor (HGF) and branched chain amino acids (BCAA) deserve closer attention. High-quality vegetable rather than animal proteins have been suggested to form an excellent dietary source of BCAA, and leucine seems the best candidate for supplementation given its stimulating effects on liver function in general and on HGF secretion specifically. Research on optimal ways of administration of HGF in dogs with MAPSS secondary to congenital portosystemic shunt attenuation is necessary before clinical trials can be initiated.

scholarly journals Oral sodium phenylbutyrate for hyperammonemia associated with congenital portosystemic shunt: a case report

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Takeshi Sato ◽  
Tomohiro Ishii ◽  
Mototoshi Kato ◽  
Takayuki Oyanagi ◽  
Seishi Nakatsuka ◽  
...  
Keyword(s):  
Portosystemic Shunt ◽  
Psychomotor Development ◽  
Case Presentation ◽  
The Third ◽  
Congenital Portosystemic Shunt ◽  
Low Levels ◽  
Portal Veins ◽  
Branched Chain ◽  
Oral Sodium ◽  
Sodium Phenylbutyrate

AbstractObjectivesThe efficacy of sodium phenylbutyrate (SPB) for hyperammonemia associated with congenital portosystemic shunt (CPSS) remains unknown. We show the effectiveness of oral SPB.Case presentationOur patient had CPSS with severe hypoplasia of extrahepatic portal veins. At 9 months of age, to assess the efficacy of oral SPB, we evaluated the 24 h fluctuations of venous ammonia levels. In the first two days without SPB, ammonia levels were above 80 μmol/L for half a day. On the third and fourth days, administration of oral SPB three times a day decreased ammonia to acceptable levels, except at midnight. On the fifth day, another oral SPB administration at 8 pm decreased ammonia at midnight. Low levels of branched-chain amino acids, as well as coagulation disturbances, were observed without apparent symptoms. At 12 months of age, he showed normal psychomotor development.ConclusionsOral SPB may be effective for hyperammonemia associated with CPSS.

scholarly journals Congenital portosystemic shunt occlusion with an Amplatzer PFO occlusion device: a case report

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Michelle M. Shnayder ◽  
Mario Dervishi ◽  
Alexandria Jo ◽  
Benjamin Pomerantz
Keyword(s):  
Treatment Guidelines ◽  
Vena Cava ◽  
Hepatopulmonary Syndrome ◽  
Portosystemic Shunt ◽  
High Morbidity ◽  
Venous Flow ◽  
Occlusion Device ◽  
Portosystemic Shunts ◽  
Congenital Portosystemic Shunt ◽  
Shunt Occlusion

Abstract Background Congenital portosystemic shunts are embryological malformations in which portal venous flow is diverted to the systemic circulation. High morbidity and mortality are seen in patients with concurrent hepatic encephalopathy, hepatopulmonary syndrome, and pulmonary hypertension. Endovascular therapy, in the correct patient population, offers a less invasive method of treatment with rapid relief of symptoms. Case presentation In this report, we discuss the treatment of a two-year-old male with abnormal chorea-like movements, altered mental status, anisocoria and hyperammonemia diagnosed with an intrahepatic congenital portosystemic shunt between the inferior vena cava and right portal vein. Given the patient’s amenable anatomy and shunt type, embolization was performed with an 18 mm Amplatzer patent foramen ovale occlusion device. Conclusions Portosystemic shunts are a rare congenital abnormality without universal treatment guidelines. An Amplatzer PFO occlusion device can provide a novel method of shunt closure given appropriate shunt type, size and anatomy.

The Weight Loss Effects of Branched Chain Amino Acids and Vitamin B6: A Randomized Controlled Trial on Obese and Overweight Women

2018 ◽  
Vol 88 (1-2) ◽  
pp. 80-89 ◽  
Author(s):  
Zahra Shakibay Novin ◽  
Saeed Ghavamzadeh ◽  
Alireza Mehdizadeh
Keyword(s):  
Amino Acids ◽  
Weight Loss ◽  
Body Composition ◽  
Vitamin B6 ◽  
Controlled Trial ◽  
Density Lipoprotein ◽  
Branched Chain Amino Acids ◽  
Model Assessment ◽  
Waist To Hip Ratio ◽  
Branched Chain

Abstract. Branched chain amino acids (BCAA), with vitamin B6 have been reported to improve fat metabolism and muscle synthesis. We hypothesized that supplementation with BCAA and vitamin B6 would result in more weight loss and improve body composition and blood markers related to cardiovascular diseases. Our aim was to determine whether the mentioned supplementation would affect weight loss, body composition, and cardiovascular risk factors during weight loss intervention. To this end, we performed a placebo-controlled randomized clinical trial in 42 overweight and obese women (BMI = 25–34.9 kg/m2). Taking a four-week moderate deficit calorie diet (–500 kcal/day), participants were randomized to receive BCAA (6 g/day) with vitamin B6 (40 mg/day) or placebo. Body composition variables measured with the use of bioelectrical impedance analysis, homeostatic model assessment, and plasma insulin, Low density lipoprotein, High density lipoprotein, Total Cholesterol, Triglyceride, and fasting blood sugar were measured. The result indicated that, weight loss was not significantly affected by BCAA and vitamin B6 supplementation (–2.43 ± 1.02 kg) or placebo (–1.64 ± 1.48 kg). However, significant time × treatment interactions in waist to hip ratio (P = 0.005), left leg lean (P = 0.004) and right leg lean (P = 0.023) were observed. Overall, supplementation with BCAA and vitamin B6 could preserve legs lean and also attenuated waist to hip ratio.

Branched chain amino acids decrease top-down event-related potentials in healthy subjects

2007 ◽  
Vol 40 (05) ◽  
Author(s):  
AH Neuhaus ◽  
TE Goldberg ◽  
Y Hassoun ◽  
JA Bates ◽  
KW Nassauer ◽  
...  
Keyword(s):  
Amino Acids ◽  
Healthy Subjects ◽  
Event Related Potentials ◽  
Branched Chain Amino Acids ◽  
Top Down ◽  
Related Potentials ◽  
Branched Chain
Sign in / Sign up

Export Citation Format

Share Document